- Home
- RPRX vs FMS Comparison
RPRX vs FMS Comparison
Compare RPRX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- FMS
- Stock Information
- Founded
- RPRX 1996
- FMS 1996
- Country
- RPRX United States
- FMS Germany
- Employees
- RPRX N/A
- FMS N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- FMS Misc Health and Biotechnology Services
- Sector
- RPRX Health Care
- FMS Health Care
- Exchange
- RPRX Nasdaq
- FMS Nasdaq
- Market Cap
- RPRX 13.9B
- FMS 15.9B
- IPO Year
- RPRX 2020
- FMS 1996
- Fundamental
- Price
- RPRX $36.03
- FMS $28.46
- Analyst Decision
- RPRX Strong Buy
- FMS Hold
- Analyst Count
- RPRX 3
- FMS 1
- Target Price
- RPRX $47.33
- FMS $30.00
- AVG Volume (30 Days)
- RPRX 4.3M
- FMS 395.6K
- Earning Date
- RPRX 08-07-2025
- FMS 07-29-2025
- Dividend Yield
- RPRX 2.44%
- FMS 1.99%
- EPS Growth
- RPRX 37.60
- FMS 27.83
- EPS
- RPRX 2.45
- FMS 2.28
- Revenue
- RPRX $2,263,845,000.00
- FMS $21,068,786,202.00
- Revenue This Year
- RPRX $29.35
- FMS $2.74
- Revenue Next Year
- RPRX $7.58
- FMS $3.60
- P/E Ratio
- RPRX $14.72
- FMS $25.09
- Revenue Growth
- RPRX 1.13
- FMS 0.10
- 52 Week Low
- RPRX $24.05
- FMS $17.93
- 52 Week High
- RPRX $36.32
- FMS $30.46
- Technical
- Relative Strength Index (RSI)
- RPRX 64.81
- FMS 51.55
- Support Level
- RPRX $35.01
- FMS $26.16
- Resistance Level
- RPRX $36.14
- FMS $28.23
- Average True Range (ATR)
- RPRX 0.70
- FMS 0.35
- MACD
- RPRX 0.10
- FMS -0.10
- Stochastic Oscillator
- RPRX 90.07
- FMS 63.92
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.